Key stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
Tuesday was the deadline for public comments on the Centers for Medicare & Medicaid Services’ (CMS) proposed rule for Medicare hospital outpatient prospective payments in 2023. CMS said in July it fully expects next year to resume paying average sales price plus 6% for hospitals’ 340B purchased drugs after paying ASP minus 22.5% since 2018. It solicited the public’s advice about how to apply the Supreme Court’s decision to payments it made during the past five years.
340B stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
